Pathological Mechanism and Targeted Drugs of COPD

Overview

Journal Int J Chron Obstruct Pulmon Dis

Publisher Dove Medical Press

Specialty Pulmonary Medicine

Date 2022 Jul 20

PMID 35855746

Authors

Peng Guo

Rui Li

Tie Hua Piao

Chun Lan Wang

Xiao Lu Wu

Hong Yan Cai

Affiliations

Soon will be listed here.

Abstract

Chronic obstructive pulmonary disease (COPD) includes chronic bronchitis, emphysema, and small airway obstruction. Incompletely reversible airflow limitation, inflammation, excessive mucus secretion and bronchial mucosal epithelial lesions are the main pathological basis of the disease. The prevalence of COPD is increasingly worldwide, which has caused the burden on individuals and society. This paper summarizes the pathogenesis of COPD and clarifies the effect and mechanism of the latest targeted drugs for COPD. Besides, we focus on NOD-like receptor thermal protein domain associated protein 3 inflammasome (NLRP3 inflammasome). NLRP3 can promote production of interleukin-1β (IL-1β) and interleukin-18 (IL-18). NLRP3 is an important factor in the migratory aggregation of macrophages and neutrophils and the generation of oxidative stress. Inhibition of NLRP3 inflammasome indirectly blocks the inflammatory effects of IL-1β and IL-18, which may be regarded as an ideal target for COPD treatment.

Citing Articles

Research advances in polyphenols from Chinese herbal medicine for the prevention and treatment of chronic obstructive pulmonary disease: a review.

Zhang Y, Wang L, Zeng J, Shen W Naunyn Schmiedebergs Arch Pharmacol. 2025; .

PMID: 40035820 DOI: 10.1007/s00210-025-03945-y.

The Therapeutic Potential of Supersulfides in Oxidative Stress-Related Diseases.

Pan Y, Matsunaga T, Zhang T, Akaike T Biomolecules. 2025; 15(2).

PMID: 40001475 PMC: 11852411. DOI: 10.3390/biom15020172.

The impact of smoking on respiratory rehabilitation efficacy and correlation analysis in patients with chronic obstructive pulmonary disease: a retrospective study.

Li M, Gao W J Thorac Dis. 2025; 17(1):254-264.

PMID: 39975758 PMC: 11833573. DOI: 10.21037/jtd-24-1267.

Comparing effects of breathing exercises alone and combined with breathing-stretching exercises on respiratory indices, disease severity and exercise capacity in COPD.

Zare F, Karimyar Jahromi M, Rahmanian Z, Faseleh Jahromi M Sci Rep. 2025; 15(1):5068.

PMID: 39934204 PMC: 11814402. DOI: 10.1038/s41598-025-89664-z.

The Effective Compound Combination of Bufei Yishen Formula III Improves the Mitochondrial Dysfunction via Inhibiting JNK/Sab Pathway in COPD Mice.

Song M, Han M, Zhang H, Yang Y, Tian Y, Li J Drug Des Devel Ther. 2025; 19:525-538.

PMID: 39876989 PMC: 11774103. DOI: 10.2147/DDDT.S487074.

References

Wang Z, Locantore N, Haldar K, Ramsheh M, Beech A, Ma W . Inflammatory Endotype-associated Airway Microbiome in Chronic Obstructive Pulmonary Disease Clinical Stability and Exacerbations: A Multicohort Longitudinal Analysis. Am J Respir Crit Care Med. 2020; 203(12):1488-1502. PMC: 8483235. DOI: 10.1164/rccm.202009-3448OC. View

Starrett W, Blake D . Sulforaphane inhibits de novo synthesis of IL-8 and MCP-1 in human epithelial cells generated by cigarette smoke extract. J Immunotoxicol. 2011; 8(2):150-8. DOI: 10.3109/1547691X.2011.558529. View

Nachmias N, Langier S, Brzezinski R, Siterman M, Stark M, Etkin S . NLRP3 inflammasome activity is upregulated in an in-vitro model of COPD exacerbation. PLoS One. 2019; 14(5):e0214622. PMC: 6529002. DOI: 10.1371/journal.pone.0214622. View

Kim R, Pinkerton J, Essilfie A, Robertson A, Baines K, Brown A . Role for NLRP3 Inflammasome-mediated, IL-1β-Dependent Responses in Severe, Steroid-Resistant Asthma. Am J Respir Crit Care Med. 2017; 196(3):283-297. DOI: 10.1164/rccm.201609-1830OC. View

An X, Wei Z, Ran B, Tian H, Gu H, Liu Y . Histone Deacetylase Inhibitor Trichostatin A Suppresses Cell Proliferation and Induces Apoptosis by Regulating the PI3K/AKT Signalling Pathway in Gastric Cancer Cells. Anticancer Agents Med Chem. 2020; 20(17):2114-2124. DOI: 10.2174/1871520620666200627204857. View

Raherison C, Girodet P . Epidemiology of COPD. Eur Respir Rev. 2010; 18(114):213-21. DOI: 10.1183/09059180.00003609. View

Criner G, Celli B, Brightling C, Agusti A, Papi A, Singh D . Benralizumab for the Prevention of COPD Exacerbations. N Engl J Med. 2019; 381(11):1023-1034. DOI: 10.1056/NEJMoa1905248. View

Salvi S, Barnes P . Chronic obstructive pulmonary disease in non-smokers. Lancet. 2009; 374(9691):733-43. DOI: 10.1016/S0140-6736(09)61303-9. View

Tse H, Raiteri L, Wong K, Yee K, Ng L, Wai K . High-dose N-acetylcysteine in stable COPD: the 1-year, double-blind, randomized, placebo-controlled HIACE study. Chest. 2013; 144(1):106-118. DOI: 10.1378/chest.12-2357. View

10.

Nasri A, Foisset F, Ahmed E, Lahmar Z, Vachier I, Jorgensen C . Roles of Mesenchymal Cells in the Lung: From Lung Development to Chronic Obstructive Pulmonary Disease. Cells. 2021; 10(12). PMC: 8700565. DOI: 10.3390/cells10123467. View

11.

Pelaia C, Vatrella A, Sciacqua A, Terracciano R, Pelaia G . Role of p38-mitogen-activated protein kinase in COPD: pathobiological implications and therapeutic perspectives. Expert Rev Respir Med. 2020; 14(5):485-491. DOI: 10.1080/17476348.2020.1732821. View

12.

Li D, Shao R, Wang N, Zhou N, Du K, Shi J . Sulforaphane Activates a lysosome-dependent transcriptional program to mitigate oxidative stress. Autophagy. 2020; 17(4):872-887. PMC: 8078734. DOI: 10.1080/15548627.2020.1739442. View

13.

Mizumura K, Maruoka S, Shimizu T, Gon Y . Role of Nrf2 in the pathogenesis of respiratory diseases. Respir Investig. 2019; 58(1):28-35. DOI: 10.1016/j.resinv.2019.10.003. View

14.

Fahy W, Homayoun-Valiani F, Cahn A, Robertson J, Templeton A, Meeraus W . Nemiralisib in Patients with an Acute Exacerbation of COPD: Placebo-Controlled, Dose-Ranging Study. Int J Chron Obstruct Pulmon Dis. 2021; 16:1637-1646. PMC: 8184152. DOI: 10.2147/COPD.S309320. View

15.

Barnes P, Burney P, Silverman E, Celli B, Vestbo J, Wedzicha J . Chronic obstructive pulmonary disease. Nat Rev Dis Primers. 2016; 1:15076. DOI: 10.1038/nrdp.2015.76. View

16.

Criner G, Celli B, Singh D, Agusti A, Papi A, Jison M . Predicting response to benralizumab in chronic obstructive pulmonary disease: analyses of GALATHEA and TERRANOVA studies. Lancet Respir Med. 2019; 8(2):158-170. DOI: 10.1016/S2213-2600(19)30338-8. View

17.

Sun X, Chen L, He Z . PI3K/Akt-Nrf2 and Anti-Inflammation Effect of Macrolides in Chronic Obstructive Pulmonary Disease. Curr Drug Metab. 2019; 20(4):301-304. DOI: 10.2174/1389200220666190227224748. View

18.

Lee U, Choung S, Prakash K, Lee E, Lee M, Kim Y . Dual knockdown of p65 and p50 subunits of NF-kappaB by siRNA inhibits the induction of inflammatory cytokines and significantly enhance apoptosis in human primary synoviocytes treated with tumor necrosis factor-alpha. Mol Biol Rep. 2007; 35(3):291-8. DOI: 10.1007/s11033-007-9084-4. View

19.

Agusti A, Fabbri L, Singh D, Vestbo J, Celli B, Franssen F . Inhaled corticosteroids in COPD: friend or foe?. Eur Respir J. 2018; 52(6). DOI: 10.1183/13993003.01219-2018. View

20.

Hoffmann A, Levchenko A, Scott M, Baltimore D . The IkappaB-NF-kappaB signaling module: temporal control and selective gene activation. Science. 2002; 298(5596):1241-5. DOI: 10.1126/science.1071914. View